Intas Pharmaceuticals in collaboration with its global Accord brand subsidiaries, has acquired UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc., becoming a leading supplier of pegfilgrastim. UDENYCA, a biosimilar to Amgen’s Neulasta (pegfilgrastim), significantly expands Intas and Accord’s FDA-approved biosimilar portfolio and strategic growth plans in the global biosimilar market. Accord was the first to commercialize a pegfilgrastim biosimilar in Europe and the only company...